EZH2 and B-cell non-Hodgkin lymphoma: Indeed, pharmacologic inhibition of EZH2 is highly effective for the treatment of murine Ezh2-mutant B-cell lymphomas as well as EZH2-mutant-patient-derived xenograft (PDX) models in vivo (Béguelin et al., 2013; Béguelin et al., 2016; Scholze et al., 2020).